Prot #HPN-CTCL-01: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date7/29/15 → 7/29/21

Funding

  • Soligenix, Inc. (Prot #HPN-CTCL-01)